Get the Stockscreener App
5.99
0.00%
0.00
After Hours:
6.00
0.010
+0.17%
Camp 4 Therapeutics Corp stock is traded at $5.99, with a volume of 67,183.
It is up +0.00% in the last 24 hours and up +84.31% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$5.99
Open:
$6.01
24h Volume:
67,183
Relative Volume:
0.40
Market Cap:
$310.77M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-1.4624
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
+1.70%
1M Performance:
+84.31%
6M Performance:
+318.88%
1Y Performance:
+33.11%
1-Day Range:
$5.75
$6.26
1-Week Range:
$5.62
$6.43
52-Week Range:
$1.305
$7.305
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
5.99 | 310.77M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Insilico’s big gain after Hong Kong listing: Finance Report - BioCentury
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit By Investing.com - Investing.com Australia
Camp4 Therapeutics signs new Watertown lease, accelerates Cambridge exit - Investing.com
CAMP4 Therapeutics Restructures Leases and Expands Facilities - TipRanks
Deal Watch: Boehringer Signs On For Rectify’s Chronic Kidney Disease Assets - Citeline News & Insights
Is Camp4 Therapeutics Corporation a good long term investmentMarket Timing Techniques & Superior Capital Trading - earlytimes.in
Will Camp4 Therapeutics Corporation stock benefit from green energy trends2025 Technical Overview & Real-Time Buy Signal Notifications - Улправда
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Sector Review & Real-Time Volume Triggers - Улправда
Market Rankings: How Camp4 Therapeutics Corporation stock performs in rate cut cyclesWeekly Trade Recap & Community Trade Idea Sharing - Улправда
Will Camp4 Therapeutics Corporation stock deliver better than expected guidanceTrade Entry Report & Long-Term Safe Investment Ideas - Улправда
GSK Deal Is Key Validation For CAMP4's Drug Discovery Platform: Analyst - Benzinga
Quarterly Recap: Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Chart Watch & Detailed Earnings Play Alerts - Улправда
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
How Camp4 Therapeutics Corporation stock performs in rate cut cyclesJuly 2025 Update & Weekly High Momentum Picks - Улправда
CAMP4 Therapeutics (Nasdaq:CAMP) Enters Research and License Agreement with GSK - Kalkine Media
CAMP4 Therapeutics Announces $28 Million Common Stock Offering - TipRanks
CAMP4 Therapeutics (CAMP) to raise about $28M in 5M-share equity deal - Stock Titan
Will Camp4 Therapeutics Corporation stock outperform international peersGap Down & Advanced Technical Analysis Signals - Улправда
CAMP4 Therapeutics and GSK partner on ASO development for diseases By Investing.com - Investing.com Nigeria
CAMP4 Therapeutics prices $30 million common stock offering By Investing.com - Investing.com Nigeria
CAMP4 and GSK enter strategic collaboration to advance RNA-based therapeutic discoveries - PharmaLive
CAMP4, GSK form RNA therapeutics collaboration agreement - TipRanks
CAMP4 Therapeutics prices $30 million common stock offering - Investing.com India
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock - The Manila Times
CAMP4 Therapeutics and GSK partner on ASO development for diseases - Investing.com
Biotech offering to raise $30M for RNA drugs on genetic diseases - Stock Titan
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries - The Manila Times
CAMP4 Therapeutics (NASDAQ: CAMP) inks GSK ASO deal with $17.5M upfront, up to $440M milestones - Stock Titan
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock By Investing.com - Investing.com Australia
CAMP4 Therapeutics Corporation (CAMP) Slides 6% in Pre-market: Without a Fresh Catalyst - Stocks Telegraph
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock - Investing.com India
Following a 46% Decline Over Last Year, Recent Gains May Please Camp4 Therapeutics Corporation (NASDAQ:CAMP) Institutional Owners - 富途牛牛
After losing 46% in the past year, Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional owners must be relieved by the recent gain - simplywall.st
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year - Yahoo Finance
Camp4 Therapeutics (CAMP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CAMP4 Therapeutics Corporation (CAMP) -6.6% in After-hours: Without a Clear Catalyst - Stocks Telegraph
Activity Recap: How Camp4 Therapeutics Corporation stock valuations compare to rivalsQuarterly Growth Report & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
[424B3] Camp4 Therapeutics Corp Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
How Camp4 Therapeutics Corporation stock performs in interest rate cyclesEntry Point & Safe Entry Zone Tips - newser.com
Will Camp4 Therapeutics Corporation stock split again soonQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
Chart based exit strategy for Camp4 Therapeutics CorporationQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Best data tools to analyze Camp4 Therapeutics Corporation stock2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Will earnings trigger a reversal in Camp4 Therapeutics Corporation2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
Can Camp4 Therapeutics Corporation stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):